ERT, or enzyme replacement therapy, is a treatment for rare genetic conditions where the body can’t produce enough of a specific enzyme needed to break down certain substances inside cells. Without that enzyme, waste materials accumulate and damage organs over time. ERT works by delivering a lab-made version of the missing enzyme directly into the bloodstream through an IV infusion, typically every one to two weeks for the rest of a patient’s life.
How ERT Works Inside Your Cells
Your cells contain tiny compartments called lysosomes that act as recycling centers. Lysosomes use specialized enzymes to break down complex sugars, fats, proteins, and other materials into smaller building blocks the cell can reuse. They also help neutralize toxins and pathogens that enter the cell. When one of these enzymes is missing or deficient due to a genetic mutation, the undigested material piles up inside the lysosome, eventually interfering with cell function and causing progressive organ damage.
ERT delivers a functioning version of the missing enzyme into the bloodstream. Once infused, the replacement enzyme binds to receptors on cell surfaces, gets pulled inside through a natural uptake process, and is shuttled directly to the lysosomes where it’s needed. There, it picks up where the deficient enzyme left off, breaking down the accumulated material. This process was discovered through a phenomenon called “cross-correction,” where researchers found that cells could absorb enzymes from their environment and route them to the right internal compartment, as long as the enzymes carried the correct chemical tags.
Conditions Treated With ERT
ERT is approved for a specific group of inherited conditions known as lysosomal storage diseases. Each one involves a different missing enzyme and affects different organs, but they share the same underlying problem of toxic buildup inside cells. The diseases currently treated with FDA-approved ERT include:
- Gaucher disease (type 1): Causes an enlarged liver and spleen, low blood counts, and bone damage. It has the most treatment options, with three separate approved enzyme therapies.
- Fabry disease: Leads to progressive kidney damage, heart problems, and nerve pain.
- Pompe disease: Affects muscles, including the heart and the muscles used for breathing. Separate products exist for the infantile-onset and late-onset forms.
- MPS I (Hurler, Hurler-Scheie, and Scheie syndromes): Causes skeletal abnormalities, organ enlargement, and in severe forms, developmental delay.
- MPS II (Hunter syndrome): Similar to MPS I, with progressive damage to multiple organ systems.
- MPS VI (Maroteaux-Lamy syndrome): Primarily affects bones, joints, and connective tissue.
What Infusions Look Like
ERT is given intravenously, usually every other week, though some patients with more severe disease receive weekly infusions. A single session takes roughly four hours for a standard dose, and over six hours at higher doses. Infusions are often started in a hospital or clinical setting, but many patients eventually transition to home infusion once their medical team confirms they tolerate the treatment well.
Because ERT replaces an enzyme that the body continuously needs, it is a lifelong commitment. Missing infusions allows waste material to start accumulating again, so consistent treatment is essential. For children diagnosed early, therapy begins in infancy and continues indefinitely.
Side Effects and Immune Reactions
The most common side effect is an infusion-associated reaction, which can include fever, chills, flushing, nausea, or skin reactions. These tend to occur most often in the early months of treatment, particularly in patients whose bodies produce little or none of the natural enzyme. In Fabry disease, for example, infusion reactions occur in about 24% to 67% of patients depending on which specific product is used.
A more significant concern is the development of antibodies against the replacement enzyme. Because the body recognizes the infused enzyme as foreign, the immune system can mount a response. Roughly 24% to 73% of Fabry disease patients develop these antibodies, depending on the treatment. In some cases, antibodies neutralize the enzyme and reduce its effectiveness. Research has found that once neutralizing antibodies form, they tend to persist for a decade or longer. Pre-treatment with antihistamines and steroids can help manage infusion reactions, and slowing the infusion rate also reduces the likelihood of symptoms.
What ERT Cannot Do
ERT’s biggest limitation is the brain. The replacement enzyme travels through the bloodstream but cannot cross the blood-brain barrier, the tightly sealed layer of cells that protects the brain from foreign substances. This means ERT is ineffective against the neurological symptoms of lysosomal storage diseases. That is a major gap, because roughly 75% of lysosomal storage diseases involve some degree of brain involvement. For conditions like severe MPS I (Hurler syndrome), where cognitive decline is a core feature, ERT alone is not enough, and patients may need additional interventions like bone marrow transplantation.
ERT also cannot reverse damage that has already occurred. It slows or stops the accumulation of harmful material, which can stabilize organ function and improve symptoms like fatigue, pain, and organ enlargement. But structural damage to bones, heart valves, or other tissues that existed before treatment began generally persists. This is why early diagnosis and treatment matter so much for these conditions.
Alternatives to ERT
Substrate reduction therapy, or SRT, takes the opposite approach. Instead of adding the missing enzyme to break down accumulated material, SRT uses an oral medication to reduce the production of that material in the first place. By partially blocking the creation of the substance the body can’t process, SRT keeps it from building up as fast. The practical advantage is significant: SRT is a pill taken at home rather than an hours-long IV infusion at a clinic. It is currently approved as an alternative for Gaucher disease and is being studied for other conditions.
Some patients switch between ERT and SRT over the course of their treatment, or use them at different stages of the disease. For conditions with severe brain involvement, researchers are exploring ways to get enzymes past the blood-brain barrier, including direct injection into the spinal fluid and engineering enzymes that can hitch a ride on natural transport systems in the brain’s blood vessels.
Cost of Treatment
ERT is one of the most expensive categories of medication in the world. Annual costs for a single patient commonly reach into the hundreds of thousands of dollars, and for some conditions, costs can exceed that depending on body weight and dosing frequency. This expense reflects both the complexity of manufacturing biological enzymes and the extremely small patient populations for each disease. Insurance coverage, government programs, and manufacturer assistance programs help offset costs in many countries, but access remains uneven globally.